Systemic Therapy Combined with Locoregional Therapy Improved Survival in Oligometastatic Breast Cancer: A Single-Center Retrospective Cohort Study

Figure 4

Subgroup analysis of progression-free survival (PFS). HR: hormone receptor; HER2: human epidermal growth factor receptor 2; DFI: disease-free interval.